Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 7,287 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 7,287 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the transaction, the chief financial officer owned 49,788 shares of the company’s stock, valued at approximately $4,579,500.24. This represents a 12.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, January 26th, Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total value of $101,288.07.
• On Thursday, January 22nd, Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $132,621.93.

Mirum Pharmaceuticals Trading Up 4.2%

Shares of Mirum Pharmaceuticals stock opened at $96.55 on Wednesday. The company’s 50-day moving average price is $96.13 and its 200-day moving average price is $81.00. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $109.28. The company has a market cap of $5.83 billion, a price-to-earnings ratio of -201.14 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). The firm had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. Mirum Pharmaceuticals’s revenue was up 49.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.00 EPS. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum completed enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases, a key clinical milestone that keeps the program on track; topline data are expected in Q4 2026. This is a material near‑term catalyst that can materially re‑rate the stock if results are positive. Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli Mirum Completes Enrollment (Yahoo)
• Negative Sentiment: Multiple insiders (CEO Christopher Peetz, COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe and Joanne Quan) sold meaningful blocks of shares on March 16 — collectively several million dollars at an average price of ~$91.98 — reducing their holdings by double‑digit percentages. Large, clustered insider sales can be perceived as profit‑taking or concern about near‑term upside and may put pressure on the stock even though insiders still retain significant equity. SEC filings: Peetz Form 4 Radovich Form 4 Bjerkholt Form 4 Howe Form 4 Quan Form 4

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Comerica Bank lifted its holdings in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. AQR Capital Management LLC increased its stake in Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after acquiring an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Mirum Pharmaceuticals by 7.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after acquiring an additional 1,720 shares during the last quarter. Caxton Associates LLP purchased a new stake in Mirum Pharmaceuticals during the first quarter valued at about $217,000. Finally, Empowered Funds LLC lifted its stake in Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. TD Cowen increased their price objective on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. HC Wainwright boosted their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Leerink Partners decreased their target price on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.